

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.07
Change (%)	▲ 0.04 (1.97%)
Volume	56,023
52 Week Low	\$1.75
Market Cap	\$19,282,013
Rolling EPS	0.14
PE Ratio	14.7857
Shares Outstanding	9,314,982

Data as of 11/15/18 3:59 p.m. ET



Recent Headlines & Events

11/13/18 - 8:00 a.m.
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

11/08/18 - 8:01 a.m.
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third

There are currently no events scheduled.

Quarter 2018 Financial Results and Recent Highlights

10/25/18 - 8:01 a.m.

Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

SEC Filings

Filing Date	Form
11/14/18	10-Q
11/13/18	8-K
10/25/18	8-K
10/04/18	8-K

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	34	10.11	44.8	4,175,184
Mutual Fund	11	.33	1.5	140,555
Director and Officer	1	.01	0.0	3,164

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,486	17.8	0	09/30/18
Sabby Management, LLC	679,408	7.3	679,408	05/29/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Renaissance Technologies LLC	367,941	4.0	205,660	09/30/18
Intracoastal Capital, L.L.C.	335,466	3.6	335,466	07/11/18
MSD Partners, L.P.	138,432	1.5	-160	09/30/18
The Vanguard Group, Inc.	125,394	1.4	1,403	09/30/18
Creative Planning, Inc.	45,677	0.5	8,475	09/30/18
Virtu Americas LLC	24,457	0.3	24,457	09/30/18
PanAgora Asset Management Inc.	16,698	0.2	1,109	09/30/18

Data provided by Nasdaq. Minimum 15 minutes delayed.